Enobia develops therapies to treat serious genetic bone disorders for which there are no approved treatments. Our lead product, A subcutaneous enzyme replacement therapy with affinity for bone that is currently in clinical trials.A subcutaneous enzyme replacement therapy with affinity for bone that is currently in clinical trials.ENB-0040 (human recombinant tissue non-specific alkaline phosphatase), is a subcutaneous bone-targeted enzyme replacement therapy for hypophosphatasia and is currently in Phase 2 clinical studies.
A rare, inherited, and sometimes fatal metabolic bone disease characterized by poor bone mineralization and profound skeletal defects.Hypophosphatasia is a rare genetic skeletal dysplasia characterized by skeletal hypomineralization. Symptoms include failure to thrive, respiratory insufficiency, rickets, myopathy and seizures in infants; rickets, myopathy, poor growth, non-traumatic fractures and early loss of primary teeth in children; and osteomalacia or "soft bones", frequent non-traumatic fractures, bone pain and early permanent tooth loss in adults.